Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

632
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
632
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

626
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
626
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

1.6K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.6K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.9K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

2.0K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

395
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
395

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Young adults' perceptions and experiences in using mobile apps and wearables for health: a qualitative study with public involvement.

BMC public health·2026
Same author

Instrumental assessment of Sit-to-Stand in Parkinson's disease: a scoping review.

Journal of neuroengineering and rehabilitation·2026
Same author

How people with cancer experience the ethical dimensions of physiotherapy in cancer rehabilitation: a qualitative interview study.

Archives of physiotherapy·2026
Same author

Development of a Central Sensitization Inventory short form using data from twenty-three countries.

The journal of pain·2026
Same author

Crafting the ideal multidimensional active ageing intervention with wearables for older adults: insights from a qualitative study.

BMC geriatrics·2026
Same author

Ethical and bioethical issues in physical therapy: A systematic scoping review.

Physical therapy·2026

Related Experiment Video

Updated: May 3, 2026

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.3K

Polypharmacy in heart failure patients.

Vittoria Mastromarino1, Matteo Casenghi, Marco Testa

  • 1Cardiology Department, Clinical and Molecular Medicine Department, Faculty of Medicine and Psychology, Sapienza University of Rome, Ospedale Sant'Andrea Via di Grottarossa 1035-1039, 00189, Rome, Italy, vittoriamastromarino@libero.it.

Current Heart Failure Reports
|February 5, 2014
PubMed
Summary
This summary is machine-generated.

Managing heart failure (HF) involves complex drug regimens, often leading to polypharmacy in elderly patients. Newer care models like self-care and telemonitoring are needed to address challenges in HF treatment.

Related Experiment Videos

Last Updated: May 3, 2026

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.3K

Area of Science:

  • Cardiology
  • Geriatrics
  • Pharmacology

Background:

  • Heart failure (HF) management frequently involves multiple medications, as recommended by guidelines.
  • Elderly HF patients often have comorbidities, increasing their pill burden and risk of polypharmacy.
  • Polypharmacy (≥5 chronic medications) is a significant issue in HF, impacting adherence, drug interactions, and adverse effects.

Purpose of the Study:

  • To highlight the challenges of polypharmacy in heart failure management.
  • To emphasize the need for evolving primary care models for complex HF patients.
  • To introduce innovative strategies for improving HF patient care.

Main Methods:

  • Review of current heart failure treatment guidelines and challenges.
  • Analysis of the impact of polypharmacy on HF patient outcomes.
  • Exploration of emerging HF care models.

Main Results:

  • Polypharmacy is common in heart failure, particularly in the elderly with comorbidities.
  • It leads to suboptimal treatment, including poor adherence, drug interactions, and adverse events.
  • Current HF patient demographics necessitate advanced care approaches.

Conclusions:

  • Newer primary care models are essential for managing complex heart failure patients.
  • Self-care, telemonitoring, and natriuretic peptide-guided therapy show promise.
  • These innovative models can mitigate the adverse effects of polypharmacy in heart failure.